ArticleInternational journal of cancer2018
Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Inflammatory Biomarkers and Breast Cancer Risk: A Systematic Review of the Evidence and Future Potential for Intervention Research.International journal of environmental research and public health · 2020Pooled it
- Risk of autoimmune and rheumatic diseases in breast cancer patients with silicone breast implants.Journal of the National Cancer Institute · 2026Observational
- Female cancer incidence before and after diagnosis of primary Sjögren's disease: A retrospective cohort study.Journal of translational autoimmunity · 2026Article
- Causality Between Immune Cells, Metabolites and Breast Cancer: Mendelian Randomization and Mediation Analysis.Biochemical genetics · 2025Article
- The association between infectious agents and breast cancer: a review of the epidemiologic evidence.Breast cancer research and treatment · 2024Review
- DPPX antibody-mediated autoimmune encephalitis:the first case with breast cancer and review of the literature.Heliyon · 2024Article
- Deciphering the causal association and co-disease mechanisms between psoriasis and breast cancer.Frontiers in immunology · 2024Article
- Analysis of Breast Cancer Family History, Estrogen Receptor Status, and Breast Cancer Outcomes in Sweden.JAMA network open · 2023Article
- Article
- Characteristics of malignant tumors of digestive system and autoimmune diseases.Frontiers in genetics · 2023Article
- A Case Report of Autoimmune Phenomena With Underlying Breast Cancer: Occam's Razor Versus Hickam's Dictum.Cureus · 2022Article
- Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women.BMC medicine · 2021Article
- Thyroid dysfunction and breast cancer risk among women in the UK Biobank cohort.Cancer medicine · 2021Article
- Review
- Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis.PloS one · 2021Article
- Prediagnostic Immune Cell Profiles and Breast Cancer.JAMA network open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The female preponderance of many autoimmune diseases suggests a possible hormonal etiology. Little research exists on systemic and organ-specific autoimmune diseases and risk of breast cancer by tumor estrogen receptor (ER)- and progesterone receptor (PR)- status. Here, we evaluate associations between selected systemic and organ-specific autoimmune diseases and breast cancer risk overall and by tumor ER- and PR-status. We used linked Surveillance, Epidemiology and End Results (SEER)-Medicare data, with first female breast cancer cases ages ≥66 years identified by SEER registries (years 1992-2011; N = 209,929). We selected female controls (N = 200,000) from a stratified 5% random sample of Medicare recipients who were alive and breast cancer-free. We assessed exposures until 12 months before breast cancer diagnosis/selection using Medicare claims data. We estimated odds ratios (OR) and 99.9% confidence intervals (CI) using unconditional and multinomial logistic regression. We found reduced breast cancer risk among those with rheumatoid arthritis (OR = 0.84; 99.9% CI 0.79-0.89), systemic lupus erythematosus (OR = 0.82; 99.9% CI 0.70-0.97) and pernicious anemia (OR = 0.90; 99.9% CI 0.83-0.97) and increased risk among those with psoriasis (OR = 1.16; 99.9% CI 1.06-1.27). Statistically significant alterations in risk for rheumatoid arthritis were limited to ER-positive (+) breast cancer, whereas those for the other three conditions were further limited to ER+/PR+ breast cancer. However, only differences for rheumatoid arthritis by ER-status were statistically significant (p-heterogeneity = 0.0001). The reasons for these associations need to be investigated in future studies accounting for host characteristics and autoimmune disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.